Table 4.
Overview of complement inhibition in preeclamptic animal models compared to controls.
| Complement pathway | Complement inhibitor | Results | Animal model |
|---|---|---|---|
| Classical | sCR1 | - Reduced C3a levels and reduced elevated MAP (41) | RUPP compared to sham control rats (41) |
| Lectin | CR2-FH | - Comparable placental weights (4) | BPH/5 compared to C57BL/6J control mice (40) |
| All pathways | CR2-Crry | - Increased placental weights (40) - Inhibition of oxidative stress, proteinuria and placental dysfunction (39) |
BPH/5 compared to C57BL/6J control mice (40) Abortion-prone CBA/J X DBA/2 compared to non-abortion-prone control mice CBA/J X BALB/c (39) |
| Anapyhlatoxins | C3a and/or C5a antagonist | - Reduced increase in MAP, without altering the decreased fetal weight or VEGF (42) - C5a antagonists attenuated endothelial dysfunction (42) |
RUPP compared to sham control rats (41, 42) |
| Atrasentan | - Improvement of hypertension (43) - Comparable fetal and placental weights (43) |
RUPP compared to sham control rats (43) |
BPH, blood pressure high; MAP, mean arterial pressure; RUPP, reduced utero-placental perfusion pressure; VEGF, vascular endothelial growth factor.